

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. -10. (Cancel)

11. (Currently amended) A test kit for use in detecting the presence of a mammalian CC-chemokine receptor 2 in a biological sample comprising:

- a) at least one an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 2, wherein said antibody or antigen-binding fragment thereof inhibits binding of a ligand to the receptor; and
- b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment thereof and said mammalian CC-chemokine receptor 2 or a portion thereof.

12.-43. (Cancel)

44. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to the receptor.

45. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof binds to a human CC-chemokine receptor 2.

46. (New) The kit according to Claim 11, wherein said antibody or antigen-binding

fragment thereof inhibits binding of a chemokine to the receptor.

47. (New) The kit according to Claim 46, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP4 and combinations thereof.

48. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or fragment thereof.

49. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a human antibody or fragment thereof

50. (New) The kit according to Claim 11, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab fragment and an F(ab')₂ fragment.

51. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or fragment thereof.

52. (New) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a recombinant antibody or fragment thereof.

53. (New) The kit according to Claim 11, further comprising a second antibody or antigen-binding fragment thereof specific for a different epitope of the receptor than the said antibody or antigen-binding fragment thereof.

54. (New) The kit according to claim 53, wherein the second antibody or antigen-binding fragment thereof is labeled.

55. (New) The kit according to Claim 11, further comprising a second antibody or antigen-binding fragment thereof which binds said antibody or antigen-binding portion thereof.

56. (New) The kit according to Claim 55, wherein the second antibody or antigen-binding fragment thereof is labeled.

57. (New) The kit according to Claim 11, wherein the antibody or antigen-binding fragment thereof is lyophilized.

58. (New) The kit according to Claim 57, further comprising an acceptable diluent, excipient or carrier.

59. (New) The kit according to Claim 11, wherein the kit further comprises a second antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 2.